Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bekanamycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | GJA1 | P17302 | 1/20 | 0.88 |
| ▸ | GJB2 | P29033 | 1/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | LRAT | O95237 | 1/20 | 0.72 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bekanamycin SCHEMBL16174013 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL19917387 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL12535725 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL17265214 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL14944403 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL23879718 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL16174041 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL13018550 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL12553422 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL158427 | 1.00 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2010132839-A9 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010132757-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132757-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | ALOX15 4776/4885KDM4E 3622/4885TSHR 3452/4885 |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ATP6V1B1, GLS, NRDC | ALOX15 2838/4885KDM4E 4645/4885TSHR 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.